TL;DR
- A SAFE is not a loan or stock — it's a promise to issue equity later
- The valuation cap is the most important term — it determines how much of your company you're selling
- Multiple SAFEs stack — total dilution is almost always larger than any single SAFE suggests
Quick navigation
Introduction
If you’re raising your first round of outside capital, you’ve almost certainly encountered the term “SAFE.” A Simple Agreement for Future Equity, SAFE for short, has become the default instrument for early-stage startup financing.
According to Carta’s State of Pre-Seed: Q1 2025 report, SAFEs accounted for 90% of all pre-seed rounds on its platform in Q1 2025. A year-end review confirmed the pattern held throughout 2025—most early-stage rounds under $4 million closed on SAFEs or convertible notes, with the post-money SAFE carrying a valuation cap and no discount remaining the instrument of choice. The pitch you’ll hear from most people in the startup ecosystem is that SAFEs are the fastest, simplest way to get capital in the door. That’s largely true. What they don’t always tell you is that a SAFE is a binding legal contract that determines how much of your company you’re promising to investors—and that part of the equation rarely gets the attention it deserves.
I’ve represented founders in numerous SAFE financings. The founders who get into trouble aren’t the ones who used a SAFE. They’re the ones who signed without understanding what they signed. This guide is meant to change that.
What a SAFE Actually Is
A SAFE is not a stock. It is not a loan. It is a contract that gives an investor the right to receive equity at a later date, typically when you raise a Series A or another qualifying priced round.
The instrument exists to solve a timing problem that every early-stage company faces. At the pre-seed and seed stages, most startups don’t have the financial metrics that investors use to set a credible valuation. You may have a working product and early traction, but not enough to anchor a defensible number.
Trying to set a valuation before you’re ready creates friction. Too high, and investors pass. Too low, and you’ve given up more ownership than you’ll be comfortable with by the time you reach your Series A. Either way, the negotiation takes time and legal costs that most early-stage companies can’t justify.
A SAFE defers that conversation. The agreement includes a valuation cap, a discount rate, or both, which govern the terms of conversion when you later raise a priced round. You get capital without agreeing on what the company is worth today; the investor gets compensated for early-stage risk through favorable conversion economics; and both parties avoid a negotiation that would likely be premature.
The process advantages are real. Compared to a full preferred-stock equity round, a SAFE involves fewer documents, fewer negotiated terms, and meaningfully lower transaction costs. That efficiency is why SAFEs have become the standard instrument for early-stage financing.
But “simple” from a process standpoint is not the same as simple from a dilution standpoint. The two are very different things, and confusing them is one of the most common—and costly—mistakes I see founders make.
How a SAFE Works in a Typical Funding Round
The investor hands you a check. In return, you deliver a contractual promise to issue them stock later. Under the standard Y Combinator forms, three events determine what happens to that promise: an equity financing, a sale of the company, or a dissolution.
The most common trigger is a qualifying equity financing—often, but not necessarily, a Series A. When that round closes, SAFE holders convert into a new series of preferred stock issued in that round. The number of shares they receive depends on the specific conversion terms in their SAFE: the valuation cap, any applicable discount, and whether the instrument is structured as a pre-money or post-money SAFE.
If the company is sold before a priced round closes, the standard YC form generally entitles SAFE holders to the greater of their original investment amount or what they would receive on a fully as-converted basis. In a dissolution, SAFE holders typically rank ahead of common stockholders but behind creditors and outstanding debt.
A SAFE can sit on your cap table indefinitely. It accrues no interest and matures on no fixed date, so it is not debt in any traditional sense. But it is not equity yet. Founders who evaluate their capitalization solely on the basis of issued shares are not looking at the full picture—and that gap between what’s issued and what’s promised is exactly where dilution surprises tend to hide.
The Terms Founders Should Understand Before Signing
Most SAFEs are short documents. That brevity can give founders a false sense of security. The economic terms are consequential—four provisions in particular drive nearly all of the financial outcomes: the valuation cap, the discount, the pre-money versus post-money structure, and whatever side rights an investor manages to negotiate.
Valuation Cap
The valuation cap is the most important economic term in any SAFE. It sets the ceiling on the company valuation at which the SAFE can convert into equity. If your Series A prices the company at $20 million and your SAFE carries a $10 million cap, then the SAFE converts at roughly half the Series A price per share, so those SAFE investors receive roughly twice as many shares per dollar invested as the new Series A investors (assuming no discount or other conversion features). .
Founders have come to me having focused almost entirely on the dollar amount they raised and treated the cap as an afterthought. But that ignores the role of the cap.. In a capped SAFE, the cap is one of the central drivers of dilution: it determines how much of the company the investor is buying for each dollar invested. A $500,000 post-money SAFE with a $5 million cap implies roughly 10% ownership before the priced round, while the same $500,000 SAFE with a $10 million cap implies roughly 5%. The numbers in between are everything.
Discount
Some SAFEs use a discount rather than a cap. A 20% discount means the SAFE converts at 80% of the Series A price per share. If Series A investors pay $1.00 per share, SAFE holders convert at $0.80. Some SAFEs carry both a cap and a discount; in that structure, the investor receives whichever treatment produces more shares at the time of conversion. If your Series A valuation is well above the cap, the cap controls. If it’s lower than expected, the discount may prove more favorable to the investor.
Discounts tend to appear more frequently in later SAFE rounds where the company already has meaningful traction. Earlier SAFEs typically rely on caps alone, because the early investor’s return comes from backing you at a stage when no one else would, and the cap is how that conviction gets rewarded.
Pro Rata Rights, MFN Clauses, and Side Letters
The Y Combinator template is a starting point. What ends up in your financing documents is often something different.
Pro rata rights entitle an investor to participate in future rounds in order to maintain their ownership percentage. In isolation, that sounds like a reasonable ask from an early backer. In practice, a cap table crowded with angel investors, each holding pro rata rights, can create serious complications when you’re trying to close a Series A. Institutional investors don’t always want to negotiate with a dozen small check holders who are exercising their rights.
Most favored nation clauses automatically upgrade an investor’s SAFE to match more favorable terms you later offer to anyone else. If you issue a SAFE to a new investor at a lower cap two months after closing a previous round, an MFN clause means your earlier investors may get the same benefit, retroactively. That kind of retroactive repricing creates real friction when you’re trying to move fast.
Side letters compound these issues. Each one introduces terms that may not be visible in your core SAFE documents. By the time your Series A counsel is reviewing everything, the interaction between all of it can produce results that no one anticipated.
Why SAFEs Feel Simple but Can Get Complicated Quickly
Here is a scenario I see regularly. A founder closes a $250,000 SAFE in the spring. Another $300,000 in the summer. A third $200,000 in the fall. Each transaction closes in a week or less. Each feels like a clean, contained infusion of capital.
Then the founder starts preparing for a Series A. Counsel models the cap table and walks through the conversion math. SAFE investors are converting into 30% of the company. The founder had been thinking 10%.
That gap didn’t come from any single SAFE being unreasonable. It came from the aggregate effect of multiple SAFEs—each with its own cap, discount, and side letter provisions—all converting at the same time. The dilution that seemed manageable in each individual transaction compounded across all of them.
Cap table modeling needs to happen before your next financing—not after it closes. Run the conversion math at multiple valuation scenarios while you still have time to do something about it: raise less in aggregate, renegotiate the cap structure, or make a deliberate decision about whether a priced equity round is the cleaner path forward.
When a SAFE Makes Sense—and When It May Not
SAFEs work well in a specific set of circumstances: you are raising a relatively modest pre-seed or seed round, you need capital quickly, you are not yet in a position to defend a negotiated valuation, and your investors are comfortable working with a straightforward instrument without heavily customized economics.
The calculus shifts when the company can credibly support a real valuation and is raising enough capital that full preferred-stock documentation would give everyone better visibility. In a priced equity round, the valuation and the price per share are fixed at closing. You know exactly what ownership you are selling. There are no deferred conversion mechanics to model later—the economics are set at the outset.
That is not to say a priced round eliminates dilution. It doesn’t. What it does is make the dilution fixed and visible at the time of the transaction, rather than contingent on a future conversion event. As rounds get larger and the stakes rise, that clarity tends to matter more than the speed and simplicity a SAFE provides.
How a SAFE Differs From a Convertible Note
SAFEs and convertible notes serve the same general objective: deferring valuation until a future financing round. But they are structurally different instruments, and those differences have real consequences.
A convertible note is debt. It carries an interest rate and a maturity date. If the company does not close a qualifying conversion event before the note matures, the documents control whether the instrument converts automatically, is extended by renegotiation, or becomes immediately payable. Notes also generate issues around debt classification and balance-sheet treatment that SAFEs avoid entirely.
A SAFE is not debt. There is no interest, no maturity date, and no right to demand repayment simply because time has passed. It converts upon a qualifying event—and if that event never comes, it can remain outstanding indefinitely.
For a detailed comparison of how the two instruments differ economically, see our separate article on SAFEs versus convertible notes and our article here on certain tax considerations if the issuing company is a limited liability company instead of a C-corp.
What to Do Before You Sign or Issue a SAFE
Build a fully diluted cap table that includes every outstanding SAFE. Issued shares alone do not tell you what your ownership structure actually looks like. SAFEs represent claims on future equity that are invisible in the share count until conversion, but every sophisticated investor and acquirer calculates ownership on a fully as-converted basis from day one. Multiple SAFEs stack. The aggregate dilution can be far larger than any individual instrument suggests.
- Model your Series A at multiple valuation scenarios. Run the conversion math using an optimistic, realistic, and conservative figure. Know what you’re walking into before you’re sitting across from a Series A lead investor.
- Know whether you’re using pre-money or post-money SAFEs—and be consistent. These two structures behave differently and produce different outcomes on your cap table. If you’ve issued both forms to different investors, that inconsistency needs to be resolved before your next round, not during it.
- Get counsel before you sign. SAFE agreements look standardized. They are not always standard. Terms vary. Side letters add layers. The interaction between multiple SAFEs carrying different caps, discounts, and conversion mechanics can produce outcomes that surprise even experienced founders. A lawyer who works in this space is worth the cost.
Ready to talk through your funding options?
FOUNDERS GUIDE TO SAFE: FAQ
What is a simple agreement for future equity?
A SAFE is an investment contract that gives an investor the right to receive equity in a future financing event. It is not a loan, and it is not currently issued stock. It is a contractual promise to issue stock later, on conversion terms set at the time the SAFE is signed. Y Combinator introduced the instrument in 2013 as a faster, more founder-friendly alternative to convertible notes for early-stage companies.
How is a SAFE different from a convertible note?
A convertible note is debt. It accrues interest and has a maturity date. A SAFE carries neither. Both instruments defer the valuation question until a future priced round, but SAFEs are structurally simpler because they eliminate interest calculations and the maturity-date pressure that forces difficult renegotiations as a convertible note approaches its deadline. The structural difference also affects how each instrument appears on the balance sheet and how it is treated for certain tax purposes.
What is a valuation cap in a SAFE?
A valuation cap sets the maximum company valuation at which a SAFE can convert to equity. If your Series A values the company at $20 million and your SAFE has a $10 million cap, the SAFE holder converts as though they invested at the lower figure—receiving roughly twice as many shares per dollar invested as a Series A investor writing a comparable check. The cap is the primary mechanism for rewarding early investors, and it has a direct impact on your dilution.
Is a SAFE a security?
Yes. A SAFE is a security under federal and state securities laws, which means any issuance needs to comply with applicable registration requirements or qualify for an exemption. Most early-stage SAFE financings rely on exemptions under Regulation D, typically Rule 506(b) or Rule 506(c), depending on the nature of your outreach and the characteristics of your investors. Which exemption applies to your specific situation is a question your counsel should confirm before you accept any funds.
What happens if a SAFE never converts?
If the company never closes a qualifying financing, is never sold, and never dissolves, a SAFE can remain outstanding indefinitely. Unlike a convertible note, it does not mature, accrue interest, or give the investor the right to demand repayment simply because time has passed.
This content is provided for informational purposes only and does not constitute legal advice. For guidance specific to your company and financing structure, contact a qualified attorney.
